公开(公告)号：US20160068912A1

公开(公告)日：2016-03-10

申请号：US14481884

申请日：2014-09-09

Applicant: Kuwait University

Inventor： FAHD AL-MULLA ,  JEAN PAUL THIERY ,  MILAD S. BITAR

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158

Abstract: The method for determining risk of metastatic relapse in a patient diagnosed with colorectal cancer (CRC) can include detecting a level of at least one indicator of metastatic potential in a biological sample from the patient, comparing the level of the indicator of metastatic potential with a control, and identifying the patient as one who is at risk of metastatic relapse and a candidate for chemotherapy if an aberrant level of the indicator of metastatic potential in the biological sample compared to the control is detected. The at least one indicator of metastatic potential can include at least one metastasis-inducing gene and/or at least one metastasis suppressor gene. An aberrant level of the at least one indicator of metastatic potential can include a copy number gain of the metastasis-inducing gene and/or a copy number loss of the metastasis-suppressor gene.

Abstract translation: 用于确定诊断为结肠直肠癌（CRC）的患者的转移性复发风险的方法可包括检测来自患者的生物样品中至少一种转移潜能指标的水平，将转移潜能指标的水平与 控制并将患者识别为具有转移性复发风险的患者，如果检测到生物样品中的转移潜能指标的异常水平，则检测化疗候选者。 转移潜能的至少一个指标可以包括至少一个转移诱导基因和/或至少一个转移抑制基因。 转移潜能的至少一个指标的异常水平可以包括转移诱导基因的拷贝数增益和/或转移抑制基因的拷贝数丢失。

公开(公告)号：US20150352064A1

公开(公告)日：2015-12-10

申请号：US14301301

申请日：2014-06-10

Applicant: Kuwait University

Inventor： MILAD S. BITAR ,  FAHD AL-MULLA

IPC: A61K31/19 ,  C12N15/113

CPC classification number: A61K31/19 ,  A61K31/56 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/3233

Abstract: The method of treating delayed healing of a wound associated with diabetes includes administering to the wound a composition comprising an anti-senescence compound and a pharmaceutically acceptable carrier. The anti-senescence compound may be 18α-Glycyrrhetinic acid, a Caveolin-1 (Cav-1) inhibitory compound, or a Polymerase I Transcript Release Factor (PTRF-1) inhibitory compound. The anti-senescence compound may be effective in preventing and/or reversing premature cellular senescence. The anti-senescence compound may be effective in promoting healing of a wound, e.g., delayed or incompletely healed wound. The anti-senescence compound may be effective in promoting healing of a delayed healing wound or chronic wound of a diabetic patient, such as a diabetic ulcer or venous ulcer.

Abstract translation: 治疗与糖尿病相关的伤口的延迟愈合的方法包括向伤口施用包含抗衰老化合物和药学上可接受的载体的组合物。 抗衰老化合物可以是18α-甘草次酸，窖蛋白-1（Cav-1）抑制化合物或聚合酶I转录物释放因子（PTRF-1）抑制化合物。 抗衰老化合物可以有效预防和/或逆转过早的细胞衰老。 抗衰老化合物可有效促进伤口愈合，例如延迟或不完全愈合的伤口。 抗衰老化合物可有效促进糖尿病患者如糖尿病性溃疡或静脉溃疡的延迟愈合伤口或慢性伤口的愈合。

公开(公告)号：US20180311193A1

公开(公告)日：2018-11-01

申请号：US16020517

申请日：2018-06-27

Applicant: KUWAIT UNIVERSITY

Inventor： MILAD S. BITAR ,  FAHD AL-MULLA

IPC: A61K31/19 ,  A61K31/56 ,  C12N15/113

CPC classification number: A61K31/19 ,  A61K31/56 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/3233

Abstract: The method of treating delayed healing of a wound associated with diabetes includes administering to the wound a composition comprising an anti-senescence compound and a pharmaceutically acceptable carrier. The anti-senescence compound may be 18α-Glycyrrhetinic acid, a Caveolin-1 (Cav-1) inhibitory compound, or a Polymerase I Transcript Release Factor (PTRF-1) inhibitory compound. The anti-senescence compound may be effective in preventing and/or reversing premature cellular senescence. The anti-senescence compound may be effective in promoting healing of a wound, e.g., delayed or incompletely healed wound. The anti-senescence compound may be effective in promoting healing of a delayed healing wound or chronic wound of a diabetic patient, such as a diabetic ulcer or venous ulcer.

公开(公告)号：US20150080236A1

公开(公告)日：2015-03-19

申请号：US14028457

申请日：2013-09-16

Applicant: KUWAIT UNIVERSITY

Inventor： FAHD AL-MULLA ,  JEAN PAUL THIERY

IPC: G01N33/68

CPC classification number: G01N33/6872 ,  G01N33/57415

Abstract: The method of sub-classifying breast cancer tumors profiles the expression of the Raf kinase inhibitor protein (RKIP) from a tissue sample from a cancerous primary breast tumor. The RKIP expression is profiled using its mRNA or by immunohistochemical protein quantifying methods in order to detect the level of RKIP in the breast cancer tissue sample. Based upon the RKIP expression profile, a sub-classification of cancer type may then be assigned. An RKIP expression of approximately 10.31 indicates basal carcinoma, an RKIP expression of approximately 10.04 indicates Claudin-low carcinoma, an RKIP expression of approximately 10.47 indicates Luminal-A carcinoma, an RKIP expression of approximately 10.44 indicates Luminal-B carcinoma, an RKIP expression of approximately 10.25 indicates HER2+ carcinoma, an RKIP expression of approximately 10.43 indicates ER+ carcinoma, and an RKIP expression of approximately 10.30 indicates ER− carcinoma.

Abstract translation: 对乳腺癌肿瘤进行亚分类的方法从癌性原发性乳腺肿瘤的组织样品中分析Raf激酶抑制蛋白（RKIP）的表达。 使用其mRNA或通过免疫组织化学蛋白质定量方法分析RKIP表达，以检测乳腺癌组织样品中RKIP的水平。 基于RKIP表达谱，然后可以分配癌症类型的亚分类。 约10.31的RKIP表达表示基底癌，约10.04的RKIP表达表示紧密连接蛋白低表达，约10.47的RKIP表达指示Luminal-A癌，约10.44的RKIP表达指示Luminal-B癌，RKIP表达 约10.25表示HER2 +癌，RKIP表达约10.43表示ER +癌，RKIP表达约10.30表示ER-癌。